Skip to main content

Table 1 Baseline characteristics of each group before intervention and over 15 years old and bone age 15 years (Mean ± SD)

From: Estrogen replacement therapy: effects of starting age on final height of girls with chronic kidney disease and short stature

Variables Group 1 (n = 16) Group 2 (n = 22) Group 3 (n = 21) P value
FH (cm) 154.5 ± 1.4a 151.6 ± 2.3b 146.1 ± 2.3c < 0.001
FH SD scorea −1.14 ± 0.22a −1.59 ± 0.36b −2.44 ± 0.36c < 0.001
MPH (cm) 159.5 ± 2 161.3 ± 3.2 160.3 ± 3 0.15
GH therapy before EE (month) 37.8 ± 6 52.9 ± 8
Lumbar (L1-L4) Density Z Score
 Primary −3 ± 0.5  
 Final −2.3 ± 0.3a −2.8 ± 0.5b −3.1 ± 0.6b < 0.001
Femur Head Density Z Score
 Primary −3.5 ± 0.7 −3.4 ± 0.7
 Final − 2.6 ± 0.4a −2.9 ± 0.4a −3.5 ± 0.5b < 0.001
Ca (mg/dl)
 Primary 8.7 ± 0.2 8.7 ± 0.2
 Final 8.8 ± 0.1a 8.7 ± 0.2a 8.4 ± 0.2b < 0.001
Ph (mg/dl)
 Primary 6.9 ± 0.4 6.7 ± 0.5
 Final 6.2 ± 0.3a 5.9 ± 0.3b 7.4 ± 0.4c < 0.001
PTH (pg/ml)
 Primary 166 ± 0.2 176 ± 0.1
 Final 143 ± 27a 155 ± 27a 279 ± 49b < 0.001
FeP (%)
 Primary 4.6 ± 0.1 4.9 ± 0.1
 Final 8.3 ± 1.9 8.6 ± 2.5 8.4 ± 0.2 0.862
  1. One-Way ANOVA was used for Value analysis
  2. Value presented as mean ± SD
  3. In each row dissimilar values (a, b, c) are significantly different
  4. aFinal Height SD score according to the CDC growth chart for stature of 2-20 years old girls